USAQ: Strong Fundamental Growth, Strong Industry Trends, and Strong Technicals Line Up


One of the defining trends that will drive a major part of the economy over the next decade is the decentralization of the healthcare system.

Home health spending, an excellent measure of this trend, is expected increase at a faster rate through 2027 than all other categories of care, according to a recent analysis from the Centers for Medicare & Medicaid Services (CMS) Office of the Actuary.

It is expected to reach more than $186 billion in 2027, according to the report. This is miles above any other category of health care service, including hospital inpatient care, physician and professional services, nursing facilities, prescription drugs, retail sales of medical products and literally everything else in the space.

That growth reflects one simple point: that the economics of the traditional hospital model for healthcare has toppled from its own weight.

The pandemic simply accelerated this trend, driving the healthcare decentralization trend into a rapid acceleration, boosting telehealth, home healthcare, and the consolidation of medical offices into larger outpatient care centers offering ambulatory surgery centers, urgent cares and sophisticated diagnostic and treatment facilities.

At the center of this constellation of concepts is a striking opportunity for new healthcare technology solutions that help to reshape the relationship between patients and providers to take full advantage of the greater efficiency on offer as this landscape evolves.

One company now at the heart of this transformative opportunity is USA Equities Corp (OTCMKTS:USAQ), a Medical Technology SaaS focused holding company that equips physicians with the digital solutions needed to increase revenues through value-based tools that evaluate and treat chronic disease, producing greater efficiency, better outcomes, and stronger unit economics.

 

Symbol:  USAQ
Company:  USA Equities Corp
Quote:  http://finance.yahoo.com/q?s=USAQ
Latest News:  http://finance.yahoo.com/q/h?s=USAQ+Headlines
Company Website: www.usaqcorp.com

Who is USAQ

USA Equities Corp (OTCMKTS:USAQ) engages in the provision of medical device technology and software as a services. 

It focuses on enabling primary care physicians to increase their revenues by providing them with relevant, value-based tools to evaluate, and treat chronic disease through reimbursable procedures. Its products will enable physicians to diagnose and treat patients with chronic diseases which they historically have referred to specialists. 

Given the skyrocketing costs associated with acute and chronic care in a centralized healthcare model, this revolutionary shift has the potential to contribute to powerful gains in cost and care efficiencies.

According to the company, “Our products improve clinical outcomes for patients – often saving them the time and expense of a specialist visit while allowing physicians to increase their practice revenue through existing reimbursement codes. We provide our clients with the software and training necessary to improve clinical outcomes using value-based healthcare, informatics, and algorithmically personalized medicine to manage behavior-based, remote patient monitoring, chronic care, and preventive medicine.”

On December 20, 2019, USA Equities Corp completed a share exchange whereby it acquired Medical Practice Income, Inc. (MPI). The Company is focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. 

The Company’s products are intended to allow the general practice physician to increase his revenues by cost effectively diagnosing and treating chronic diseases generally referred to specialists. The Company’s products and information service portfolio are directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population. 

According to recent company communications, USAQ is projecting entry level monthly subscriptions will be $299/month or $3,588 per year. Its near-term projection is to acquire 5,000 physician clients by the end of 2023 and over 20,000 physicians in the medium to longer term, which is still less than five percent of the total target physician audience in the US today. 

According to the Journal of Pharma and Healthcare: “There are over 450,000 primary care physicians, including licensed nurse practitioners, in the United States.” 

With a range between $3,588 – $10,000 per physician per year, USAQ is targeting an addressable annual market of roughly $1.6 billion. Capturing just 5% of this market would generate revenue of at least $87 million.

The company’s near-term objective is to acquire five thousand physicians by 2023, which would generate $17.9 million on the topline. All current and future products and services will be sold through the same distribution channel and customer base allowing it to generate additional revenue without the customer acquisition cost. 

Additional future distribution channels will come from licensed nurse practitioners starting their own private practices, walk-up clinics at pharmacies, urgent care clinics in grocery stores, and workplace health clinics for the large self-insured employers seeking healthcare cost savings by providing their employees with cost effective access to primary health care at their place of work. 

For a more in-depth profile, the company was recently featured in an audio podcast on SmallCapVoice.com, which can be accessed here.

Recent Catalysts

Positive Coverage. Most recently, the company announced the publication of a research report on USAQ by global research firm, Litchfield Hills Research LLC. The report, which was accessible on Bloomberg, FactSet, NASDAQ, NYSE Connect, S&P Cap IQ, Thomson Reuters (Refinitiv) and 12 other platforms around the globe, rated the Company a “Buy” under its three-tiered (buy-hold-sell) rating system, with a target price of $5.00 per share.

“Litchfield Hills research report highlights the strong sequential improvement in revenue and gross margin we saw in our first quarter financial results. We have made significant progress over the past few months with the commercial launch of AllergiEnd®’s allergy diagnostic and Allergen immunotherapy products expansion of our management team and visibility in the industry among primary care physicians. We continue to expect an increase in revenue and gross margin in the second quarter of 2021,” said Troy Grogan, CEO of USA Equities Corp.

Booming Growth. The company also recently announced results from a breakout quarter of growth during the 3-months ended March 31, 2021, including strong sequential growth and expectations for the second quarter.

“We made excellent progress executing on our financial and strategic priorities in the first quarter of 2021,” stated USAQ Chief Executive Officer Troy Grogan. “On a sequential basis, our revenue more than doubled to approximately $304,000, while gross margin improved 370 basis points to 43.9%. This growth is due to increased sales of allergy diagnostic kits and immunotherapy treatments as well as expansion of our customer base We also saw continued momentum in April, and currently expect an increase in revenue and gross margin in the second quarter of 2021.”

Expanding Braintrust. The company also recently announced that it has appointed Mr. Mike Mangus to its advisory and physician network development team. Mike will provide strategic guidance in the expansion of the Company’s physician network in conjunction with the Company’s automated cloud-based SaaS digital medicine and virtual care system.

“Mike has shown an invaluable depth of experience in the medical device and technology industry. His demonstrated business and physician network development at previous fortune 1,000 medical companies is expected to be an important contribution to the next phase of commercialization of our digital medicine and virtual care technologies at USAQ,” said Troy Grogan, President and CEO at USA Equities Corp.

This is important given the company’s strong guidance and objectives around expanding its physician network to drive accelerating growth over coming quarters.

Technical Analysis

USAQ has been tracing out a very large Bullish Ascending Triangle breakout pattern for the better part of the past two years. The rule of thumb among technical analysts is: the longer such a triangle breakout pattern has been building, the more explosive its eventual breakout stands to be, potentially.

Nothing in life is remotely guaranteed, and anything is possible in markets.

But, no matter how you slice it, this type of pattern is often very promising. A clear breakout and close above $0.70 would be the trigger for the pattern, in theory.

About USAQ

USAQ (USA Equities Corp) is focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care, and preventive medicine. 

The Company’s products are intended to allow the general practice physician to increase his revenues by cost effectively diagnosing and treating chronic diseases generally referred to specialists. 

The Company’s products and information service portfolio are directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. 

Its principal objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic, and cardiovascular disease population.

Key Points:

  • USAQ drove strong topline growth in Q1, with revs topping $300k, representing whopping q/q sequential growth of 144%
  • USAQ gross margin improved 370 basis points to 43.9% in Q1
  • USAQ has seen breakout sales of its Allergy Diagnostic Kits and Immunotherapy Treatments to start 2021
  • USAQ also recently projected another sequential increase in Gross Margin in Q2 2021
  • USAQ just recorded a MACD Bullish reversal, suggesting a technical change in trend.
  • USAQ is positioning itself as a leader in core technology aligned with the powerful healthcare decentralization trend, which is rounding the shoulder of an apparently exponential growth curve in developed countries

Conclusion

USAQ is an impressive small-cap in an impressive industry context. The drive to find new disruptive innovations that help scale powerful healthcare treatment solutions with improved outcomes, a wider footprint, and better unit economics at the provider level has taken root and depends on new technology solutions such as those on offer from this innovative name.

Recent results prove the model to some extent, as USAQ sees very strong growth across core metrics and establishes a realistic growth plan with achievable but impressive objectives for coming quarters.

The company is squaring off with a large and growing total addressable market and making rapid strides toward top positioning in its niche.

And, technically, USAQ shares are locked in a clear “Bullish Ascending Triangle” pattern that potentially points to breakout upside action ahead.

Recent Chart Activity

Recent News

-Further Expanding Independent Practitioner Network and Industry Visibility- West Palm Beach, FL, June 09, 2021 (GLOBE NEWSWIRE) -- USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, today announced it has entered into a co-promotion agreement with ENP Network, the largest web-based services provider to the nurse practitioner (NP) community and nurse practitioner associations with over 260,000 members. ENP Network will

West Palm Beach, FL, May 27, 2021 (GLOBE NEWSWIRE) -- USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, announced today, equity research firm, Litchfield Hills Research LLC, released its analyst coverage report on USAQ for first quarter 2021 results for the period ended March 31, 2021, rating the Company a "Buy" under its three-tiered (buy-hold-sell) rating system, with a target price of $5.00 per share. As of the end of its last trading day, USAQ's shares closed at $.68 per share. "Litchfield Hills research report highlights the strong sequential improvement in revenue and gross margin we saw in our first quarter financial results. We have made significant progress over the past few months with the commercial launch of AllergiEnd®’s allergy diagnostic and Allergen immunotherapy products expansion of our management team and visibility in the industry among primary care physicians. We continue to expect an increase in revenue and gross margin in the second quarter of 2021” said Troy Grogan, CEO of USA Equities Corp. Litchfield Hills Research adheres to FINRA standards for quality and objectivity. The Litchfield Hills Research Department certifies its report is compliant with FINRA research rules 2241, 3110. Litchfield’s price target, financial models, peer comparisons, and investment thesis are developed without input from management of the company, and they perform their own USAQ due diligence. The research report is MiFID II compliant and is classified as minor non-monetary benefit under MiFID II. It is accessible on Bloomberg, FactSet, NASDAQ, NYSE Connect, S&P Cap IQ, Thomson Reuters (Refinitiv) and 12 other platforms around the globe. It will be posted to the research firm’s website http://www.hillsresearch.com/current-research/ About USA Equities Corp. USA Equities Corp. (OTCQB: USAQ) is focused on providing value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior-based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow general practice physicians to increase revenues by cost effectively diagnosing and treating chronic diseases that are generally referred to specialists. The Company’s products and information service portfolio are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, point of care devices and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today’s allergy prone, obese, diabetic and cardiovascular disease population. For additional information, visit the Company’s website at www.USAQCorp.com Forward-Looking Statements Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products and the acceptance of these products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investor & Media Contact: Olivia Giamanco USA Equities Corp (929) 379-6503 IR@USAQCORP.COM

AUSTIN, TX / ACCESSWIRE / May 20, 2021 / SmallCapVoice. ("SCV") announces the availability of a new interview with Troy Grogan, CEO of USA Equities Corp.

● Substantial Sequential Increase in Revenue and Gross Margin ● Growth in Customer Base and Revenue Per Customer Compared to Q4 2020 ● Company Expects Sequential Increase in Gross Margin in Q2 2021 ● USAQ Medical Advisory Board Presenting at the University of Miami Miller School of Medicine CME Workshop on June 26, 2021 West Palm Beach, FL, May 18, 2021 (GLOBE NEWSWIRE) -- USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, today announces its first-quarter financial results for the period ended March 31, 2021, reporting strong sequential growth and setting expectations for the second quarter. “We made excellent progress executing on our financial and strategic priorities in the first quarter of 2021,” stated USAQ Chief Executive Officer Troy Grogan. “On a sequential basis, our revenue more than doubled to approximately $304,000, while gross margin improved 370 basis points to 43.9%. This growth is due to increased sales of allergy diagnostic kits and immunotherapy treatments as well as expansion of our customer base We also saw continued momentum in April, and currently expect an increase in revenue and gross margin in the second quarter of 2021.” Business Highlights “From a strategic perspective, several significant accomplishments in the quarter further strengthened our business model and management team. We amended our distribution agreement with MedScience Research Group regarding AllergiEnd®’s allergy diagnostic and Allergen immunotherapy products; as a result, our distribution fee payment to MedScience was reduced by 20%, which will substantially increase our gross margin beginning with the second quarter of 2021. We also announced the appointment of Michael Mangus to our advisory and physician network development team. Mike is a highly experienced and respected executive in the medical device and technology industry, and I believe he will be a valuable addition as we further commercialize our digital medicine and virtual care technologies,” stated Grogan. “Additionally, increased visibility of USAQ in the industry through participation in continuing medical education programs focused on our core markets is contributing to our success. As the number of potential physician clients for our products and services contacted by us expands, so does the level of positive customer feedback we receive. For example, in March, five of our medical advisory board members presented at the inaugural University of Miami Allergy Diagnostics and Allergen Immunotherapy Virtual CME event. Our team will also participate in a similar workshop at the University of Miami’s Miller School of Medicine on June 26, 2021. Through these events, we are able to further educate medical practitioners regarding our solutions to enhance patient quality of life through physician-directed digital medicine as well as driving revenue opportunities for physicians in their own practices. “In sum, we believe we are in the early stages of building a robust medical device technology and software platform supported by significant recurring revenue, large and growing addressable markets, and a highly energized management and advisory team. Our targeted solutions enable primary care physicians to provide preventive solutions with value-based digital tools to evaluate and treat chronic disease through reimbursable procedures. Over time, we expect to launch additional products and services which will further grow our revenue per customer and client base while leveraging our cost structure,” concluded Grogan. First Quarter 2021 Financial Results *USAQ began selling AllergiEnd® Allergy Diagnostics and Allergen Immunotherapy treatments in the fourth quarter of 2020. ● Revenues for the three months ended March 31, 2021, were $304,336, an increase over revenues of $124,532 reported in the fourth quarter of 2020 due to growth in both Allergy Diagnostic Kits and Immunotherapy Treatment sales, which the Company initiated in the fourth quarter of 2020. ● First-quarter 2021 sales of Allergy Diagnostic Kits were $187,040 compared to fourth-quarter 2020 sales of $77,210; first-quarter 2021 sales of Immunotherapy Treatments were $107,853 compared to sales of $43,586 in the prior quarter. ● The Company generated gross profit of $133,579, or a gross margin of approximately 43.9%, in first quarter 2021 compared to gross profit of $50,093 or a gross margin of 40.2% in fourth quarter 2020. The increase was primarily attributable to the larger base of sales as well as customer and product mix. ● Sales and marketing expenses of $111,688 in first quarter 2021 compared to $66,120 for fourth quarter 2020, as we hired additional personnel and further expanded the launch of our products. ● General and administrative expenses of $70,127 in first quarter 2021 compared to $94,343 in fourth quarter 2020. About USA Equities Corp. USA Equities Corp. (OTCQB: USAQ) is focused on providing value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior-based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow general practice physicians to increase revenues by cost effectively diagnosing and treating chronic diseases that are generally referred to specialists. The Company’s products and information service portfolio are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, point of care devices and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today’s allergy prone, obese, diabetic and cardiovascular disease population. For additional information, visit the Company’s website at www.USAQCorp.com Forward-Looking Statements Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products and the acceptance of these products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investor & Media Contact: Olivia Giamanco USA Equities Corp (929) 379-6503 IR@USAQCORP.COM

West Palm Beach, FL, May 13, 2021 (GLOBE NEWSWIRE) -- USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, today announced that it has engaged several firms in the area of corporate communications, investment community outreach and strategic partnering to further expand the Company’s visibility and level of investor and corporate community engagement. “We have made significant progress over the past few months. The successful commercial launch of AllergiEnd® products, our recently amended agreement with MedScience Research Group which will increase our gross margin and the expansion of our advisory and physician network development team to increase our presence with medical practitioners are just a few of the recent examples of our successful execution on our strategic priorities,” stated USAQ Chief Executive Officer Troy Grogan. “Given our expectation for continued growth at USAQ, I am also very pleased to announce our new relationships with ClearView Advisors Group, Milestone Management Services and SmallCap Voice.com, all highly experienced firms that will assist us in expanding our outreach. I look forward to working closely with these firms to communicate our future successes and further growing our public profile,” concluded Grogan. About ClearView Advisors Group ClearView Advisors Group is a financial communications firm which leverages its comprehensive experience to create customized communication programs that support client messaging strategies and goals for both public and private companies. For additional information, visit the Company’s website at www.clearviewadv.com About Milestone Management Services Milestone provides Micro-Cap and Small-Cap companies with Strategic Advisory, Financial Public Relations, Investor Relations and Media Services. Milestone directs efficient and effective conversations that drive business objectives, enhance reputations and build meaningful relationships with entrepreneurs and venture capitalists, along with institutional and high-level retail investors. For additional information, visit the Company’s website at www.milestonemanagementservices.com About SmallCapVoice.com. SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.SmallCapVoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/. About USA Equities Corp. USA Equities Corp. (OTCQB: USAQ) is focused on providing value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior-based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow general practice physicians to increase revenues by cost effectively diagnosing and treating chronic diseases that are generally referred to specialists. The Company’s products and information service portfolio are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, point of care devices and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today’s allergy prone, obese, diabetic and cardiovascular disease population. For additional information, visit the Company’s website at www.USAQCorp.com Forward-Looking Statements Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products and the acceptance of these products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investor & Media Contact: Olivia Giamanco USA Equities Corp (929) 379-6503 IR@USAQCORP.COM

WEST PALM BEACH, FL, Feb. 23, 2021 (GLOBE NEWSWIRE) -- USA EQUITIES CORP. (OTCQB: USAQ) (the “Company,” “we,” or “our”) is focused on enabling primary care physicians (PCP’s) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease through reimbursable point of care and SaaS procedures. The Company announced today that it has appointed Mr. Mike Mangus to its advisory and physician network development team. Mike will provide strategic guidance in the expansion of the Company’s physician network in conjunction with the Company’s automated cloud-based SaaS digital medicine and virtual care system. “Mike has shown an invaluable depth of experience in the medical device and technology industry. His demonstrated business and physician network development at previous fortune 1,000 medical companies is expected to be an important contribution to the next phase of commercialization of our digital medicine and virtual care technologies at USAQ,” said Troy Grogan, President and CEO at USA Equities Corp. Mike Mangus has a fifteen-year plus medical career in medical device sales. He worked for Atrium Medical and Dexcom, Inc. These positions helped him establish a vast network of physician, hospital, and Group Purchasing Organization (GPO) contacts throughout Florida, all of which have provided him a wealth of information and understanding of navigating both the medical sales and managed care space. In his four years with Dexcom, Mike was responsible for 700% territory growth in Florida, along with seeing both Medicare and Medicaid bring the Dexcom system for continuous glucose monitoring into their reimbursement coverage portfolio. He played an essential role in negotiating both Blue Cross Blue Shield (BCBS) of Florida, Florida Blue, and United Healthcare to cover the Dexcom system, making it accessible to all patients and providers. Mike transitioned into the “fee for service” (FFS) arena in 2012, focusing on various in-office, point-of-care tests, and the reimbursement associated with these non-invasive procedures. He oversaw enormous growth in the FFS business by providing physicians with additional avenues to increase patients’ quality of life while expanding the practice’s bottom-line revenue. Mike brings a wealth of sales experience and corporate business development knowledge to our team, and his network of nationwide physician contacts will prove highly valuable as we expand our reach in Q2 2021 and beyond. About USA Equities Corp (OTCQB: USAQ) On December 20, 2019 USA Equities Corp completed a share exchange whereby it acquired Medical Practice Income, Inc. (MPI). The Company is focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow the general practice physician to increase his revenues by cost effectively diagnosing and treating chronic diseases generally referred to specialists. The Company’s products and information service portfolio are directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population. The Company is located in West Palm Beach, Florida. For more information, visit www.USAQCorp.com Forward-Looking Statements Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investor & Media Contact:Olivia GiamancoUSA Equities Corp(929) 379-6503IR@USAQCORP.COM

WEST PALM BEACH, FL, Feb. 19, 2021 (GLOBE NEWSWIRE) -- USA EQUITIES CORP. (OTCQB: USAQ) (the “Company,” “we,” or “our”) is focused on enabling primary care physicians (PCP’s) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease through reimbursable point of care and SaaS procedures. The Company is excited to announce today that five of its medical advisory board members will be presenting at the inaugural University of Miami Allergy Diagnostics and Allergen Immunotherapy Virtual CME event on March 13, 2021. Assistant Professor of Otolaryngology, Björn Herman, MD, FACS, Fredric W. Pullen, II MD, FACS, Professor, vol., Otolaryngology, both at the University of Miami Miller School of Medicine, Dr. Frank Lichtenberger, MD, PhD, board certified allergist and Immunologist, Marcos Sanchez-Gonzalez MD, PhD and Syed Rizvi PhD, will be presenting at the conference, along with a panel of their esteemed colleagues. “We’re thrilled that the leaders of our medical advisory board and experts in the field are participating in this unique live virtual conference. At USAQ, we champion education and prioritize, equipping physicians with the tools they need to improve clinical outcomes and sustain their practices with new ancillary services and revenue streams, including continuing medical education,” said Troy Grogan, President and CEO at USA Equities Corp. According to the University of Miami’s description of the CME workshop, practitioners can expect “the training they need to diagnose, treat, and manage patients with noncomplex, non-life-threatening allergies. Physicians, nurses, nurse practitioners, physician assistants and other medical professionals who are not board-certified in allergy and immunology will develop evidence-based skills, knowledge, and confidence in the field of allergy and immunology.” “As a member of USAQ’s advisory board, it’s important to see companies emerge that prioritize the future of medicine. USAQ equips physicians with the digital tools and point of care services such as allergy testing and treatment products they desperately need to treat a wider variety of clinical issues, better serve their patients, provide opportunities for continuing education, and encourage the adoption and availability of technology,” said Fred Pullen MD, Medical Adviser at USAQ. Physicians and other health care providers can find more information about the University of Miami Allergy Diagnostics & Allergen Immunotherapy CME event at www.miami.edu/allergy About USA Equities Corp (OTCQB: USAQ) On December 20, 2019 USA Equities Corp completed a share exchange whereby it acquired Medical Practice Income, Inc. (MPI). The Company is focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow the general practice physician to increase his revenues by cost effectively diagnosing and treating chronic diseases generally referred to specialists. The Company’s products and information service portfolio are directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population. The Company is located in West Palm Beach, Florida. For more information, visit www.USAQCorp.com Forward-Looking Statements Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investor & Media Contact:Olivia GiamancoUSA Equities Corp(929) 379-6503IR@USAQCORP.COM

WEST PALM BEACH, FL, Feb. 17, 2021 (GLOBE NEWSWIRE) -- USA EQUITIES CORP. (OTCQB: USAQ) (the “Company,” “we,” or “our”) is focused on enabling primary care physicians (PCP’s) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease through reimbursable procedures. The Company announced today its newest appointments to the medical and scientific advisory board. Joining the team of leading researchers and medical experts is Björn Herman, MD, FACS, who serves as the Assistant Professor of Otolaryngology at the University of Miami Miller School of Medicine; Frank Lichtenberger, MD, Ph.D., Board Certified Internist, and Allergy Immunologist; Juan Escobar, MD. Internal Medicine; and Fredric W. Pullen, II MD, FACS, Professor, vol., Otolaryngology, at the University of Miami, Miller School of Medicine. “We are very proud that three of our new Medical Advisory Board members are also current clients” states Troy Grogan, President, and CEO at USA Equities Corp. USAQ is led by a group of concerned doctors, academics, health professionals, informatics, and information technology professionals, with a shared goal of seeing individuals take control of their health through physician-directed digital medicine and innovative, AI-enhanced, preventive health technologies that streamline the care process. We are a medical device technology company focused on enabling primary care physicians (PCP’s) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease through reimbursable point of care and SaaS procedures. Our first addition is Björn Herman, MD, FACS, who serves as the Assistant Professor of Otolaryngology at the University of Miami Miller School of Medicine. Dr. Herman graduated from Yale University before receiving his M.D. from Columbia University College of Physicians and Surgeons. He then completed his Otolaryngology residency at Jackson Memorial Hospital and the University of Miami. After residency, Dr. Herman spent three years in Ohio. He worked for Holzer Health System and was an Adjunct Assistant Professor in the Department of Otolaryngology at the Ohio State University. He returned to the University of Miami as a general otolaryngologist with a special interest in endoscopic sinus surgery in 2015, helping develop the university’s satellite clinics in Palm Beach County, and developing the Department of Otolaryngology’s allergy program. Dr. Herman has published many journals articles throughout his career, including publications in Otolaryngology-Head and Neck Surgery, the International Journal of Pediatric Otorhinolaryngology, the Annals of Otology, Rhinology, and Laryngology, the Journal of the Society of Endoscopic and Laparoscopic Surgeons, the American Journal of Surgery, and the World Journal of Surgery. Next, we’re proud to announce the addition of Frank Lichtenberger, MD, Ph.D., Board Certified Internist, and Allergy Immunologist. Dr. Lichtenberger has been practicing in North Carolina since he finished his Fellowship training at the National Institutes of Health. He is recognized by his peers and industry as an expert and thought leader in the conditions of Primary Immunodeficiency, Hereditary Angioedema, and Mast Cell Disorders. He has an independent grant to study mast cell-related inflammation markers and is active in internationally sponsored clinical trials. His wife and two young children keep him busy, but he stays active with his indoor hydroponic gardening hobbies. Industry and oversight monitoring show that he is ranked #1 in North Carolina amongst Allergy/Immunology practitioners for care complexity. Juan Escobar, MD. is an avid user of the Company’s allergy testing and treatment products, he is an internal medicine specialist who practices in Florida’s Treasure Coast area. Dr. Escobar completed his residency and training at the North Shore Medical Center, located on the North Shore of Boston, MA - the second largest community hospital system in Massachusetts. Dr. Escobar has more than 25 years practicing internal medicine in a clinical setting and is interested in anti-aging medicine. Dr. Escobar is a member of the American Academy of Anti-Aging Medicine, where he completed a fellowship in anti-aging medicine and nutrition. “I am constantly looking for innovation and ‘what’s next’ in healthcare and that’s why I’m joining Troy Grogan and his team at USAQ,” said Dr. Escobar. He also served as a Medical Director at NeuroTechnology, which worked with individuals, assisting the development of optimal brain states, a technology used to help Olympic athletes, celebrities, and individuals who want to improve memory, capacity for achievement, and a more balanced lifestyle. He believes strongly in innovation within medical practices and equipping physicians with the additional tools to transform their practices. Finally, we’re proud to announce the addition of Fredric W. Pullen, II MD, FACS, Professor, vol., Otolaryngology, at the University of Miami, Miller School of Medicine. Dr. Pullen studied bacteriology at the University of Michigan and received his Doctor of Medicine at the University of Michigan Medical School, where he published his first of many peer-reviewed scientific articles and several books. He continued his studies at Harvard Medical School and the Massachusetts Eye and Ear Infirmary/Massachusetts General Hospital in Boston, in Otorhinolaryngology. Dr. Pullen served in the United States Air Force as an ear, nose, and throat specialist and vice commander of the 7272 USAF Hospital, obtaining the Major’s rank. After his service, he returned to academic medicine at the University of Miami, becoming a clinical professor in the Otolaryngology department and a consultant to the Air Force Surgeon General. He began treatment of allergic disease using skin testing and oral and subcutaneous immunotherapy in his private practice. Dr. Pullen was a founder of Interactive Telemedicine Systems, The Hearing, Education and Research Foundation (HEAR), American Educational Designers (First use of Videotape teaching in medicine), Chief editor of Video-digest, The National Hearing Conservation Association, and Allertemp, providing allergy services to physicians offices throughout south Florida. Dr. Pullen is currently a Fellow with several leading medical organizations: American College of Surgeons, American Academy of Facial Plastic and Reconstructive Surgery (emeritus), American Academy of Otolaryngology-Head and Neck Surgery, American Laryngological, Rhinological and Otological Society, American Neurotology Society, Past President He is a member of other prestigious and respected medical organizations, including the American Academy of Otolaryngic Allergy, and the American Medical Association. Dr. Pullen is also a recipient of the Honor Award from the American Academy of Otolaryngology. About USA Equities Corp (OTCQB: USAQ) On December 20, 2019 USA Equities Corp completed a share exchange whereby it acquired Medical Practice Income, Inc. (MPI). The Company is focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow the general practice physician to increase his revenues by cost effectively diagnosing and treating chronic diseases generally referred to specialists. The Company’s products and information service portfolio are directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population. The Company is located in West Palm Beach, Florida. For more information, visit www.USAQCorp.com Forward-Looking Statements Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investor & Media Contact: Olivia Giamanco USA Equities Corp (929) 379-6503 IR@USAQCORP.COM

WEST PALM BEACH, FL, Dec. 30, 2020 (GLOBE NEWSWIRE) -- USA EQUITIES CORP. (OTCQB: USAQ) (the “Company,” “we,” or “our”) announced today that its revenues for the fourth quarter of 2020 would be approximately $120,000 and that its revenues would exceed $300,000 in the first quarter of 2021. We introduced our QHSLab, Software as a Service (SaaS) platform, to 159 medical practices in June 2020. Through September, physicians in these practices provided 374 allergy patients with a QHSLab-generated allergen immunotherapy prescription, generating an estimated $664,608 in revenue for these physicians’ practices. In November, building on the capabilities of our QHSLab, we began shipping allergy diagnostic related products and immunotherapy treatments to these physicians in response to their requests based upon courses of treatment recommended for their patients by QHSLab. Our revenue in the fourth quarter will be $120,000 as a result of these sales. Based upon orders in hand and reasonably anticipated, revenues from our allergy diagnostic test kits and treatment programs should exceed $300,000 in the first quarter of 2021. Revenues from this program should continue to increase thereafter as we increase the number of physicians and medical practices utilizing QHSLab.Based on our QHSLab allergy treatment system’s success, we intend to increase our revenues by charging physicians a monthly subscription fee for the use of QHSLab. USAQ plans to introduce these physicians to additional point of care diagnostic, digital medicine, and treatments that our physician clients can use and prescribe. They will be paid under existing government and private insurance programs, based upon analyses conducted utilizing QHSLab.The revenues we generated in the fourth quarter of 2020 and anticipated revenue in the first quarter of 2021 far exceed the revenue levels assumed by the equity research firm, Litchfield Hills Research, when it released its first analyst coverage report on USAQ. Litchfield Hills continue to rate our stock as a “buy” under its three-tiered rating system, with a target price of $5.00 per share.About USA Equities Corp (OTCQB: USAQ)On December 20, 2019 USA Equities Corp completed a share exchange whereby it acquired Medical Practice Income, Inc. (MPI). The Company is focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s products are intended to allow the general practice physician to increase his revenues by cost effectively diagnosing and treating chronic diseases generally referred to specialists. The Company’s products and information service portfolio are directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our principal objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population. The Company is located in West Palm Beach, Florida. For more information, visit www.MedicalPracticeIncome.com/discover.Forward-Looking StatementsCertain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products and potential future results and acquisitions, are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.Investor Relations Contact:  Olivia Giamanco  USA Equities Corp  (929) 379-6503  admin@medicalpracticeincome.com

West Palm Beach, FL, Dec. 10, 2020 (GLOBE NEWSWIRE) -- While the recent and rapid development of Pfizer/BioNTech's COVID-19 vaccine is undoubtedly good news, Time Magazine reported that administering this vaccine to individuals with a history of severe allergic reactions is not recommended, according to a U.K. Regulator, as the United Kingdom is the first country to begin vaccinations. This news comes after two healthcare professionals, both with a history of anaphylactoid reactions, suffered adverse side effects to the vaccine. They have since recovered. As the United States waits for the vaccine, this news from the U.K. is a cautionary warning. Physicians should begin making preparations ahead of time for those patients with a history of allergic reactions. Despite the uncertainty surrounding this vaccine, physicians can alleviate the patient's worry by providing an allergy test ahead of vaccination. Patients should explore allergy testing ahead of vaccination. Often someone discovers that they are allergic to something - only after being exposed to an allergen and experiencing the negative effects.Further complicating the issue is that approximately sixty million Americans are affected by allergic disorders. Yet, there are fewer than 3,000 practicing allergists in the U.S. Since the beginning of the COVID-19 pandemic, there has been a shift within healthcare, including an increased reliance on primary care physicians. Primary care physicians need additional resources at their disposal, now more than ever, and now that includes allergy testing."We didn't realize how critical our AllergiEnd products would become in the scope of screening patients prior to receiving the vaccine - but we are ready to distribute allergy test kits to all medical practices, pharmacies and workplace medical clinics immediately," states Troy Grogan, President, and CEO at USA Equities Corp.Our AllergiEnd tests empowers the primary care practitioners to test and begin treating allergy patients in their own offices through a safe, easy to administer, needle-free skin test designed for administration in primary care settings. Test results are available in as little as 15-20 minutes. Patients can now have confidence in knowing if they suffer from allergic reactions (and, if so, what triggers it) before considering vaccination. For more information about USAQ’s AllergiEnd or to begin providing allergy testing in your practice, please visit www.allergiend.com or contact our physician relations team member at (855) 702-1307.About USA Equities Corp (OTCQB: USAQ)USA Equities Corp. (USAQ), through its wholly owned subsidiary Medical Practice Income (MPI) a Florida corporation, is focused on value-based healthcare solutions in the digital medicine market, informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, virtual care and preventive medicine. The Company's intellectual properties, products and information service portfolio is directed towards prevention, early detection, management, and reversal of cardiometabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today's now younger, obese, diabetic and cardiovascular disease population. For more information, visit www.MedicalPracticeIncome.com/discover.Forward-Looking StatementsThis press release contains forward-looking statements identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements have not been based solely on historical facts but on USA Equities Corp’s current expectations about future events and results. You should consider that as such statements relate to future matters, they are subject to various inherent risks, uncertainties, and assumptions that could cause actual results or events to differ materially from expectations described in the forward-looking statement. Various important factors could cause actual results or events to differ materially from the forward-looking statements that USA Equities Corp makes, including, but not limited to, the risk that software development and studies may be delayed and may not have satisfactory outcomes, the risk that costs required to continue our Software as a Service (SaaS) or to expand our operations will be higher than anticipated and other risks described in the “Risk Factors” section of our Annual Report on Form 10-K filed by USA Equities Corp with the SEC on February 21, 2020. Except where required by law, USA Equities Corp. has no intention to update or revise forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events, or any other factors affect the information contained in this presentation. None of USA Equities Corp Directors, Consultants, or any other person named with their consent in this presentation can assure you that any forward-looking statement or result expressed or implied by any forward-looking statement will be achieved.Investor Relations Contact:  Olivia Giamanco  Medical Practice Income, Inc.  (929) 379-6503  admin@medicalpracticeincome.com

West Palm Beach, FL, Nov. 13, 2020 (GLOBE NEWSWIRE) -- USA Equities Corp. (OTCQB: USAQ), and its wholly owned subsidiary Medical Practice Income, a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce today, equity research firm, Litchfield Hills Research LLC released its first analyst coverage report on USAQ, rating the Company a "Buy" under its three-tiered (buy-hold-sell) rating system, with a target price of $5.00 per share. As of the end of its last trading day, USAQ's shares closed at $.62 per share."We are pleased Litchfield Hills Research initiated research and analyst coverage of USAQ. Litchfield has shown a keen interest in our digital and virtual medicine technologies and will continue to cover our company in the future," said Troy Grogan, CEO of USA Equities Corp.Litchfield Hills Research adheres to FINRA standards for quality and objectivity. The Litchfield Hills Research Department certifies its report is compliant with FINRA research rules 2241, 3110. Litchfield’s price target, financial models, peer comparisons, and investment thesis are developed without input from management of the company, and they perform their own USAQ due diligence.The research report is MiFID II compliant and is classified as minor non-monetary benefit under MiFID II. It is accessible on Bloomberg, FactSet, NASDAQ, NYSE Connect, S&P Cap IQ, Thomson Reuters (Refinitiv) and 12 other platforms around the globe. It will be posted to the research firm’s website http://www.hillsresearch.com/current-research/About USA Equities Corp (OTCQB: USAQ)On December 20, 2019 USA Equities Corp entered into and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (MPI), a Florida corporation. As a result of the Share Exchange, MPI became our wholly-owned-subsidiary. We are focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s intellectual properties, products and information service portfolio is directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population and is located in West Palm Beach, Florida. For more information, visit www.MedicalPracticeIncome.com/discover.Forward-Looking StatementsThis press release contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements have not been based solely on historical facts but on USA Equities Corp current expectations about future events and results. You should consider that as such statements relate to future matters, they are subject to various inherent risks, uncertainties and assumptions that could cause actual results or events to differ materially from expectations described in the forward-looking statement. Various important factors could cause actual results or events to differ materially from the forward-looking statements that USA Equities Corp makes, including, but not limited to, the risk that software development and studies may be delayed and may not have satisfactory outcomes, the risk that costs required to continue our Software as a Service (SaaS) or to expand our operations will be higher than anticipated and other risks described in the “Risk Factors” section of our Annual Report on Form 10-K filed by USA Equities Corp with the SEC on February 21, 2020. Except where required by law, USA Equities Corp. has no intention to update or revise forward looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation. None of USA Equities Corp Directors, Consultants, or any other person named with their consent in this presentation can assure you that any forward-looking statement or result expressed or implied by any forward-looking statement will be achieved.Investor Relations Contact: Keith Pinder Landon Capital (404) 995-6671 kpinder@landoncapital.net

WEST PALM BEACH, FL, Oct. 26, 2020 (GLOBE NEWSWIRE) -- USA EQUITIES CORP. (OTCQB: USAQ) (the “Company,” “we,” or “our”) and its wholly owned subsidiary Medical Practice Income, announced an exclusive distribution agreement (the “Agreement”) with MedScience Research Group, Inc. (“MedScience”) today. MedScience granted the Company an exclusive right to distribute its allergy diagnostics and allergen immunotherapy system and related components (the “Products”) to physicians which are not allergy specialists. Troy Grogan, President and Chief Executive Officer of USA Equities Corp., stated, “We are excited to take this next step in our plan to enhance the management of chronic diseases at the primary care level with this exclusive distribution agreement. I expect this agreement will have an immediate positive impact on USAQ’s revenue in Q4 2020. Our management and our medical advisory board have significant experience in the primary care market and view this agreement in very positive terms. As we previously disclosed, we have been evaluating opportunities within this market because of our experience, and we believe that this particular opportunity can provide tremendous value for our stockholders going forward.”MedScience’s innovative, FDA cleared, flagship product line, AllergiEnd® have already distinguished themselves as a leader in bringing allergy technology to the primary care physician’s practice. With seven issued patents, to date, including utility and method patents, as well several Federally registered trademarks, this proprietary line of diagnostic equipment and products, designed for the primary care environment, provides the non-allergy specialist physician with a broader avenue in which to practice evidence-based medicine, benefitting both the patient and the doctor’s practice. MedScience’s mission to enhance the quality of life of individuals and populations through research, evidence-based diagnostics, innovative intervention, and education, while also enhancing the physician’s practice closely aligns with the mission and goals of the Company.“We are thrilled to have the opportunity to partner with MedScience and believe MedScience’s philosophy and commitment to innovative and premium quality products closely aligns with the Company’s mission and vision and will make this a fruitful partnership for both parties. While this is just the first step, we are enthusiastic for what is to come and for the growth opportunities that this agreement represents for the company’s future,” Mr. Grogan concluded.About USA Equities Corp (OTCQB: USAQ)On December 20, 2019 USA Equities Corp entered into and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (MPI), a Florida corporation. As a result of the Share Exchange, MPI became our wholly-owned-subsidiary. We are focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s intellectual properties, products and information service portfolio is directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population and is located in West Palm Beach, Florida. For more information, visit www.MedicalPracticeIncome.com/discover.Forward-Looking StatementsThis press release contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements have not been based solely on historical facts but on USA Equities Corp current expectations about future events and results. You should consider that as such statements relate to future matters, they are subject to various inherent risks, uncertainties and assumptions that could cause actual results or events to differ materially from expectations described in the forward-looking statement. Various important factors could cause actual results or events to differ materially from the forward-looking statements that USA Equities Corp makes, including, but not limited to, the risk that software development and studies may be delayed and may not have satisfactory outcomes, the risk that costs required to continue our Software as a Service (SaaS) or to expand our operations will be higher than anticipated and other risks described in the “Risk Factors” section of our Annual Report on Form 10-K filed by USA Equities Corp with the SEC on February 21, 2020. Except where required by law, USA Equities Corp. has no intention to update or revise forward looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation. None of USA Equities Corp Directors, Consultants, or any other person named with their consent in this presentation can assure you that any forward-looking statement or result expressed or implied by any forward-looking statement will be achieved.Investor Relations Contact: Keith Pinder Landon Capital (404) 995-6671 kpinder@landoncapital.net

West Palm Beach, FL, Oct. 09, 2020 (GLOBE NEWSWIRE) -- USA Equities Corp. (OTCQB: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce today, that its common stock was approved for quotation on the OTC Markets Group, Inc.’s OTCQB® tier Venture Market (the “OTCQB”). “Up listing to the OTCQB Venture Market tier is an important milestone in USA Equities Corp’s current and future plans,” stated Troy Grogan, CEO. “We believe that the wider market exposure afforded by the OTCQB will increase our visibility within the investment community and assist in broadening our institutional shareholder base.”"Our overall focus is on enhancing diagnostics and evidence based remote monitoring capability of physicians while building a solid and profitable digital medicine, virtual care and remote patient monitoring business that will deliver meaningful economic returns to our shareholders. We believe this up listing, with its many benefits, will serve as a steppingstone to a future up listing on the NASDAQ or NYSE as we continue on our exciting growth," continued Mr. Grogan.For more information about USA Equities Corp. (USAQ) and its innovative physician directed digital medicine platform, or to become a participating physician, please visit https://www.medicalpracticeincome.com/opportunities.About USA Equities Corp (OTCQB: USAQ)On December 20, 2019 USA Equities Corp entered into and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (MPI), a Florida corporation. As a result of the Share Exchange, MPI became our wholly-owned-subsidiary. We are focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s intellectual properties, products and information service portfolio is directed towards prevention, early detection, management, and reversal of cardio-metabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population and is located in West Palm Beach, Florida. For more information, visit www.MedicalPracticeIncome.com/discover.Forward-Looking StatementsThis press release contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements have not been based solely on historical facts but on USA Equities Corp current expectations about future events and results. You should consider that as such statements relate to future matters, they are subject to various inherent risks, uncertainties and assumptions that could cause actual results or events to differ materially from expectations described in the forward-looking statement. Various important factors could cause actual results or events to differ materially from the forward-looking statements that USA Equities Corp makes, including, but not limited to, the risk that software development and studies may be delayed and may not have satisfactory outcomes, the risk that costs required to continue our Software as a Service (SaaS) or to expand our operations will be higher than anticipated and other risks described in the “Risk Factors” section of our Annual Report on Form 10-K filed by USA Equities Corp with the SEC on February 21, 2020. Except where required by law, USA Equities Corp. has no intention to update or revise forward looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation. None of USA Equities Corp Directors, Consultants, or any other person named with their consent in this presentation can assure you that any forward-looking statement or result expressed or implied by any forward-looking statement will be achieved.Investor Relations Contact:  Keith Pinder  Landon Capital  (404) 995-6671  kpinder@landoncapital.net

USA Equities Corp. (OTC Link: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce that it has begun the application process for an up-list of its common stock to the OTCQB® Venture Marketplace. Unlike the OTC PINK, the OTCQB is recognized by the Securities and Exchange Commission (SEC) as an established public market and provides current public information to investors that need to analyze, value, and trade securities. Because the OTCQB increases transparency, reporting standards, management certification and compliance requirements, this can result in greater liquidity and awareness for companies that meet the OTCQB tier standard.

West Palm Beach, FL, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Medical Practice Income (MPI), a subsidiary of USA Equities Corp. (OTC Link: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce the early success of the QHSLab launch in South Florida. Since launching the platform on June 30, 2020, 159 medical practices have provided 374 allergy patients with a QHSLab-generated allergen immunotherapy prescription, generating an estimated $664,608 in reimbursement revenue to these physicians practices. There are over 450,000 primary care physicians, including licensed nurse practitioners, in the United States. Many are reporting higher rates of fatigue and burnout due to long hours, heavy patient caseloads, and declining practice revenue from a lack of healthcare reimbursements. Primary care physicians are particularly overwhelmed by the number of patients suffering from allergies, which often signal other health related and immune compromising concerns. Doctors need smart, digital medicine solutions that save time and money, while delivering the right treatment to patients that need it. With the addition of QHSLab, not only will physicians be better equipped to treat patients, but they will also be able to sustain their practices with ongoing revenue through healthcare reimbursements, generating new income per practice, per year.Allergies alone are estimated to affect 1 in every 5 Americans and costs upwards of $18 billion in direct health and medical expenditures annually. It not only impairs quality of life, but is responsible for as much as $4 billion annually in lost productivity due to work and school absences. When over-the-counter allergy medication treatment is no longer successful, allergen immunotherapy is recommended. Allergen immunotherapy is usually prepared by allergy specialists however, today there is a published shortage of board-certified allergy specialists available to treat the number of allergy sufferers.1 Patients must now rely on their primary care provider to effectively manage their allergies. “Through our AI-enhanced, physician-directed platform, MPI’s QHSLab, we’re increasing the primary care physician’s ability to effectively address their patients chronic conditions, while saving them time and potentially expensive visits to a specialist when not absolutely necessary,” said Troy Grogan, President and CEO of Medical Practice Income, Inc and USA Equities Corp.The Fall of 2020 is soon upon us, but this season will be even more alarming than usual due to the ongoing spread and impact of COVID-19. Fredric Pullen MD, FACS, an Allergy and Ear, Nose & Throat Specialist based in Palm Beach Gardens, FL shared the following insight regarding QHSLab: “It’s so much easier for busy primary care physicians to have a software system that can automatically generate the patient’s allergy formulas for their appropriate immunotherapy, based on their allergy test results. It saves time and potential error which is a definite plus for non-allergy specialist doctors, especially in the age of COVID-19.”For more information about Medical Practice Income, or to become a participating physician, please visit https://www.medicalpracticeincome.com/opportunities.          1. American College of Allergy, Asthma and Immunology. Graduate Medical Education and Workforce Issues in Allergy and Immunology. 2008. About USA Equities Corp (OTC Link: USAQ)On December 20, 2019 USA Equities Corp entered into and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (MPI), a Florida corporation. As a result of the Share Exchange, MPI became our wholly-owned-subsidiary. We are focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s intellectual properties, products and information service portfolio is directed towards prevention, early detection, management and reversal of cardio-metabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population and is located in West Palm Beach, Florida. For more information, visit www.MedicalPracticeIncome.com/discover.Forward-Looking StatementsThis press release contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements have not been based solely on historical facts but on USA Equities Corp current expectations about future events and results. You should consider that as such statements relate to future matters, they are subject to various inherent risks, uncertainties and assumptions that could cause actual results or events to differ materially from expectations described in the forward-looking statement. Various important factors could cause actual results or events to differ materially from the forward-looking statements that USA Equities Corp makes, including, but not limited to, the risk that software development and studies may be delayed and may not have satisfactory outcomes, the risk that costs required to continue our Software as a Service (SaaS) or to expand our operations will be higher than anticipated and other risks described in the “Risk Factors” section of our Annual Report on Form 10-K filed by USA Equities Corp with the SEC on February 21, 2020. Except where required by law, USA Equities Corp. has no intention to update or revise forward looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation. None of USA Equities Corp Directors, Consultants, or any other person named with their consent in this presentation can assure you that any forward-looking statement or result expressed or implied by any forward-looking statement will be achieved.Investor & Media Contact:  Olivia Giamanco  Medical Practice Income, Inc.  (929) 374-6503  Admin@medicalpracticeincome.com

USA Equities Corp. (OTC Link: USAQ), a company focused on value-based healthcare solutions and physician-directed digital medicine, announced the launch of QHSLab, a Software as a Service (SaaS) platform today. QHSLab will be brought to the marketplace through approximately 150 primary care practices in Florida. Physicians, nurse practitioners, and ancillary medical practice staff will be active users of this platform, utilizing its proprietary algorithm initially for selecting appropriate allergen immunotherapy treatment sets for their patient populations.

Published by Pamela Garcia

Pamela Garcia is a keen follower of U.S. stock market

SignUp Now For Our Featured Newsletter